Farletuzumab: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III Study FAR 131 (MORAb-003-004) trial in 1,100 patients with platinum-sensitive epithelial ovarian cancer in first

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE